GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Revenue per Share

Ceapro (TSXV:CZO) Revenue per Share : C$0.12 (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Ceapro Revenue per Share?

Ceapro's revenue per share for the three months ended in Dec. 2023 was C$0.02. Ceapro's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.12.

Warning Sign:

Ceapro Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Ceapro was -48.80% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -14.10% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 0.40% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Ceapro's Revenue per Share or its related term are showing as below:

TSXV:CZO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -36.4   Med: 7.9   Max: 53.9
Current: -14.1

During the past 13 years, Ceapro's highest 3-Year average Revenue Per Share Growth Rate was 53.90% per year. The lowest was -36.40% per year. And the median was 7.90% per year.

TSXV:CZO's 3-Year Revenue Growth Rate is ranked worse than
73.17% of 779 companies
in the Biotechnology industry
Industry Median: 3.6 vs TSXV:CZO: -14.10

Ceapro Revenue per Share Historical Data

The historical data trend for Ceapro's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Revenue per Share Chart

Ceapro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.19 0.22 0.24 0.12

Ceapro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.02 0.03 0.02

Competitive Comparison of Ceapro's Revenue per Share

For the Biotechnology subindustry, Ceapro's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ceapro's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceapro's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ceapro's PS Ratio falls into.



Ceapro Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Ceapro's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=9.633/78.273
=0.12

Ceapro's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=1.651/78.293
=0.02

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ceapro  (TSXV:CZO) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Ceapro Revenue per Share Related Terms

Thank you for viewing the detailed overview of Ceapro's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ceapro (TSXV:CZO) Business Description

Traded in Other Exchanges
Address
7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines